PLX
Protalix Biotherapeutics Inc
2.70$
-1.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 59.7% | 16.7% | 91.3% | 72.3% | 27.2% | 19.9% | 17.3% | 42.6% | 41.1% | 35.1% | 45.5% | 52.2% | |
| 40.3% | 83.3% | 8.7% | 27.7% | 72.8% | 80.1% | 82.7% | 57.4% | 58.9% | 64.9% | 54.5% | 47.8% | |
| 180.4% | 458.9% | 330.6% | 136.8% | 97.3% | 81.6% | 60.7% | 77.5% | 61.6% | 26.1% | 24.3% | 36.1% | |
| 63.7% | 166.8% | 101.7% | 54.7% | 5.7% | 10.9% | 8.1% | 10.5% | 28.5% | 38.9% | 76.4% | 22.1% | |
| 206.5% | 625.7% | 369.2% | 191.5% | 129.2% | 99.7% | 78.4% | 110.7% | 86.2% | 48.9% | 47.1% | 58.3% | |
| -188.4% | -542.4% | -360.5% | -163.8% | -56.4% | -19.6% | 4.3% | -53.4% | -27.3% | 16.0% | 7.3% | -10.4% | |
| 32.6% | 85.6% | 45.6% | 46.1% | 22.4% | 14.6% | 15.4% | 19.6% | 5.3% | 4.9% | 2.0% | 2.3% | |
| -219.6% | -625.2% | -317.2% | -395.9% | -77.3% | -33.4% | -10.4% | -71.9% | -30.2% | 13.1% | 7.8% | -10.6% | |
| -19.4% | -2,006.6% | 118.0% | 37.0% | 1.6% | 14.6% | 13.3% | 16.7% | 1.1% | 0.4% | 2.3% | 1.9% | |
| -197.5% | 1,329.9% | -319.2% | -395.9% | -77.3% | -33.4% | -10.4% | -71.9% | -31.3% | 12.7% | 5.5% | -12.5% | |
| -166.4% | -485.3% | -250.0% | -340.6% | -49.9% | -15.9% | 7.1% | -49.4% | -22.6% | 19.8% | 12.2% | -5.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.